EUVIMEDEUVIMED entdecken
Open Access

Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction

Lin Hu iD, Yuan Su, Xi Tang, Yanfei Li, Jinhui Feng, Gefei He iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01126-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Lin Hu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Voriconazole, Drug Monitoring, Antifungal Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HSTD | Natural Science Foundation of Hunan Province (), Scientific research project of hunan provincial health commission, Scientific research project of changsha municipal health commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to describe the distribution characteristics of voriconazole (VRC) plasma trough concentrations ( C trough ) in patients with liver dysfunction, identify factors influencing VRC C trough , and provide recommendations for the use of VRC in this population. We retrospectively collected medical records of hospitalized patients with liver dysfunction who used VRC and underwent therapeutic drug monitoring (TDM) at the First Hospital of Changsha. The severity of liver dysfunction was assessed by the Child–Pugh (CP) score. Multiple linear regression was employed to explore factors affecting VRC C trough in these patients. A total of 147 C trough from 102 patients with liver dysfunction were analyzed. Patients were categorized into a control group ( n = 40), CP-A ( n = 39), CP-B ( n = 11), and CP-C group ( n = 12). The initial probability of target attainment of C trough was 70.6%, with 6.9% of patients obtaining subtherapeutic C trough and 22.5% obtaining supertherapeutic C trough . The initial C trough in CP-A and B were 5.05 (0.64–9.57) mg/L and 5.37 (0.26–10.01) mg/L, respectively, significantly higher than the control group ( P = 0.021 and P = 0.010). The proportion of VRC C trough of >5.5 mg/L in CP-A and B was 33.3% and 45.5%, respectively. Multiple linear regression analysis revealed that factors such as age ≥70 years, CP class, C-reactive protein (CRP), and direct bilirubin were significantly related to the initial VRC C trough . Among all measurements, patients with severe inflammation (CRP >100 mg/L), aged ≥70 years, and albumin levels of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleDrug MonitoringAntifungal AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedLiver DiseasesAdult

Stichwörter der Autor:innen

liver dysfunctionsafetytherapeutic drug monitoringvoriconazole

Substanzen

VoriconazoleAntifungal Agents

Autor:innen und Institutionen

  • Department of Pharmacy, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.
  • Department of Pharmacy, The First Hospital of Changsha, Changsha, Hunan, China.

ORCID-Profile: Lin Hu, Gefei He

Förderung

  • HSTD | Natural Science Foundation of Hunan Province ()
  • Scientific research project of hunan provincial health commission
  • Scientific research project of changsha municipal health commission

Zitieren

APA

Hu, L., Su, Y., Tang, X., Li, Y., Feng, J., & He, G. (2024). Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01126-24

Vancouver

Hu L, Su Y, Tang X, Li Y, Feng J, He G. Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01126-24

BibTeX
@article{Hu2024,
  author = {Hu, Lin and Su, Yuan and Tang, Xi and Li, Yanfei and Feng, Jinhui and He, Gefei},
  title = {Therapeutic drug monitoring and safety of voriconazole in patients with liver dysfunction},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01126-24}
}
Kostenlos starten →